According to Dr. Alfredo Galvez
, lead scientific advisor with Missouri-based Soy Labs, LLC
, some of the "megatrends" that are driving the nutrition market in general are directly impacting this category."An aging population, lack of confidence in traditional health care systems and globalization/consumer access to information are compelling shoppers to be proactive and seek alternative solutions to their health concerns," he
"Most cholesterol is produced in the liver by the HMG-CoA reductase gene.Statin drugs work by blocking HMGCoA, but they can often block too much," Galvez
"This leads to serious side effects because our body needs a minimum level of cholesterol for proper cellular functions such as maintaining cell membrane integrity and hormone production.
According to Galvez
, lunasin works differently: it targets cholesterol at an earlier stage than statins, reducing the HMG-CoA without blocking it entirely.
"Lunasin demonstrates superior support for cardiovascular health and exhibits significant anti-inflammatory properties," he
Compared to statins, lunasin works at an earlier stage in the process than prescription statins by reducing the expression of the HMG-CoA Reductase gene, according to Galvez
"While cholesterol is an accepted biomarker for identifying the risk factors associated with cardiovascular disease, other potential biomarkers (e.g. inflammation markers, circulating free fatty acids, etc.) are being identified that may play and equally important role in heart health," Galvez
"The key to future innovations in this segment will be finding bioactive compounds that work synergistically to support heart health by addressing the many inter-related health indicators."
Further, a new take on statins may be forthcoming.
"Recently research is considering the use of low-dose statin treatment for primary prevention of cardiovascular disease," Galvez